Please ensure Javascript is enabled for purposes of website accessibility

Why Evolus Stock Dived by Almost 19% Today

By Eric Volkman - Apr 22, 2021 at 6:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Few are smiling about the company's upcoming share issue.

What happened

Cosmetic drug specialist Evolus (EOLS 0.78%) produced investor frowns on Thursday following its announcement of a dilutive secondary share issue. The stock closed down by 18.9%, recovering only slightly in after-hours trading.

So what

Evolus is floating 9 million shares of its common stock at a price of $9.50 apiece. The underwriters of the issue have also been granted a 30-day option to buy up to an extra 1.35 million shares collectively. The company expects the issue to close on or about next Monday, April 26.

That $9.50 per share was well below Wednesday's closing stock price; the sell-off reduced the stock to roughly that level ($9.51). 

Elderly man frowning.

Image source: Getty Images.

It's not only the pricing, though -- Evolus is notably diluting existing stockholders. According to data compiled by Yahoo! Finance, the company currently has just over 43.7 million shares outstanding.

Another likely concern for investors is that Evolus is the very definition of a specialty pharmaceutical company. It has but a single product on the market, and it's the cosmetic drug Jeuveau, an injectable that temporarily erases frown lines between the eyebrows.

Now what

While Jeuveau has its adherents (Evolus managed to grow its revenue by nearly 62% last year), the company is still heavily loss-making. And as a business with an extremely narrow focus, it has no insulation against shocks in its very particular segment. Even at its new, steep discount, it doesn't feel like a compelling buy.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Evolus, Inc. Stock Quote
Evolus, Inc.
EOLS
$11.69 (0.78%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.